Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish...
Clinical Trial
Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial
Single infusion of FLT201 at low dose of 4.5e11 vg/kg demonstrates compelling safety and benefit Expect to initiate Phase 3...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development...
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical...
Bio-Path Holdings Provides Clinical Update and Expansion Plans
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for...
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply
Collaboration aims to develop innovative production methods to increase global availability of vegetables, shorten supply chains and promote sustainable agricultureHAIFA,...
Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million...
Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Signum Surgical Granted FDA De Novo Clearance for BioHealx™
Novel surgical option for the treatment of anal fistula, a painful and debilitating colorectal condition Milestone follows recent completion of...
Breast Tissue Expander Market size is set to grow by USD 282.4 million from 2024-2028, Increasing prevalence of breast cancer boost the market, Technavio
NEW YORK, July 4, 2024 /PRNewswire/ -- The global breast tissue expander market size is estimated to grow by USD 282.4 million...
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia...
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives...
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more...
MedMira Reports Third Quarter Results FY2024
HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for...
PillBot™: Micro-robotics now inside the Human Body
HAYWARD, Calif., July 2, 2024 /PRNewswire/ -- Endiatx, a pioneering Silicon Valley medical technology company, is shaping the future of...
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Vaxcyte Appoints John Furey to Board of Directors
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines...
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 DeficiencyBOSTON, July 02, 2024...
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
Dahan brings over two decades of experience in the life sciences industry transforming companies from early pre-clinical stage development to...
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...